Where and by whom is the study being conducted?
The study is being Sponsored by Intensity Therapeutics and being conducted by leading medical physician oncologists at major medical hospitals in the United States and Canada.
Whom do I contact in order to able to participate?
Please visit the clinicaltrials.gov website and search for the study using the identifier NCT03058289 to see the names, emails and phone numbers of the contact hospitals conducting the study.
Why is this study being done?
The main purpose of this study is to determine the safety of administering an investigational new drug (referred to as “INT230-6” or the “study drug”) directly into multiple superficial (you can feel them with your touch) and deep tumors (such as those within the body or inside an organ e.g. the liver). “Investigational” means that INT230-6 has not yet been approved by regulatory authorities such as the United States Food and Drug Administration (FDA) or Health Canada for use outside of clinical trials. This drug has not been given to humans prior to this study.